NovoCure (NVCR) EBT (2014 - 2026)

NovoCure has disclosed EBT across 13 years of filings, most recently posting -$12.5 million for Q2 2026.

• In Q2 2026, EBT rose 64.4% year-over-year to -$12.5 million; the TTM figure through Jun 2026 stood at -$152.7 million (down 7.48% YoY), while the FY2025 annual figure was -$136.2 million, down 3.88% from the prior year.
• EBT came in at -$12.5 million for Q2 2026 at NovoCure, up from -$69.3 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$2.5 million in Q1 2022 to a low of -$69.3 million in Q1 2026.
• Average EBT over 5 years is -$34.6 million, with a median of -$32.1 million recorded in 2022.
• Year-over-year, EBT tumbled 1931.01% in 2023 and jumped 64.4% in 2026.
• Over 5 years, EBT stood at -$32.6 million in 2022, then retreated by 18.35% to -$38.5 million in 2023, then slumped by 43.27% to -$55.2 million in 2024, then rose by 25.82% to -$41.0 million in 2025, then jumped by 69.6% to -$12.5 million in 2026.
• Per Business Quant data, the three most recent EBT figures were -$12.5 million in Q2 2026, -$69.3 million in Q1 2026, and -$41.0 million in Q4 2025.